ClinicalTrials.gg
RecruitingNCT06422078AIR POWERUpdated Aug 28, 2026

A Non-interventional, Prospective Study With Benralizumab

An observational study in Asthma, Bronchial, sponsored by AstraZeneca. Recruiting at 41 sites in Germany. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Planned enrollment
73rd of 110
300 · median 500
Started
2024
with 25 others
Observational
111 of 359
9 open now
Primary completion
2027-12
later than 15 of 27 live
Registered
320th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 73rd largest by planned enrollment of the 110 observational ones that give a count, is one of 26 that started in 2024, is one of 111 observational ones, reaches primary completion later than 15 of the 27 other live ones, and was the 320th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in a real-life setting in Germany.

Read the detailed description

This is a prospective observational study to investigate the asthma control and health realted quality of life (HRQL) of benralizumab treated patients in routine clinical practice, their asthma medication intake, and their changes in asthma medication during the study, up to 52 weeks.

The asthma control will be analyzed by using the Asthma Control Test (ACT) and the Asthma Impairment and Risk Questionnaire (AIRQ®) at different timepoints during the study period either collected by the investigator or self-reported by the patient. In addition, health realted quality of life will be assessed at baseline and routine follow-up visits using the mini Asthma Quality of Life Questionnaire (miniAQLQ) which is collected by the investigator. To investigate the medication intake and assess the changes in asthma medication, the patients will record their weekly medication intake in a paper-based or an electronic medication diary throughout the study.

03

Conditions studied

  • Asthma, Bronchial

Browse trials for

Keywords

  • benralizumab
  • severe eosinophilic asthma
  • quality of life
  • asthma control
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients, who were diagnosed with severe eosinophilic asthma treated by pulmonary specialists, for whom the indication to start benralizumab therapy was received independently of study participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 18 years or older
  • Confirmed diagnosis of severe eosinophilic asthma (defined according to the European Respiratory Society and American Thoracic Society and local German guidelines) treated with high-dose inhaled (ICS) plus long-acting beta agonists (LABA)
  • Prescribed treatment with benralizumab according to label and local market reimbursement criteria
  • Benralizumab treatment was not part of the study decision and treatment decision was met prior and independently of the study
  • Patients must be able and willing to read and comprehend written instructions
  • After full explanation, patients must have signed an form (ICF) indicating that they understand the purpose of, and the procedures required for the study and are willing to participate in the study
  • Patients must be willing to report asthma patient-reported outcomes (PROs) every 4 weeks and medication intake weekly

Exclusion criteria

Exclusion Criteria:

  • Patients who participate in an observational trial that might, in the investigators' opinion, influence the assessment for current study; or participated in a randomized clinical trial in the last 3 months
  • History of anaphylaxis to any biologic therapy
  • Prior treatment with any asthma biologic therapy within the last 3 months
  • Concurrent asthma biologic therapy
  • Helminth parasitic infection diagnosed within 24 weeks prior to the date was obtained that had not been treated with, or had failed to respond to standard of care (SOC) therapy
  • Any other pulmonary disease than asthma that, in the investigator's point of view, would have an impact on the interpretation of results
  • An acute or chronic condition that, in the investigator's point of view, would limit the patient's ability to complete questionnaires or participate in this study or impact the interpretations of results
  • Current or history of within 5 years before the enrolment date with the following exceptions:

    • In-situ carcinoma of the cervix where curative therapy has been completed and patients are in remission for at least 12 months prior to enrolment date
    • Basal cell or superficial squamous skin cancer
  • Pregnancy or lactation period (status to be proactively asked by the investigator)
  • Any condition, that, in the opinion of the investigator, could jeopardize the safety of the patient
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose

    To assess asthma control in patients initiating treatment with benralizumab over time. The ACT includes 5 questions. The score can range from 5 (worst control) to 25 (best control). Scores between 20 and 25 indicate well-controlled asthma, and scores lower than 20 indicate patients with not-well controlled asthma.

    Time frame: From baseline to week 12, 24 and 52

  2. Proportion of responders at baseline, week 12, 24 and 52 after first benralizumab dose, using ACT

    To assess asthma control in patients initiating treatment with benralizumab. Responders are defined as patients with well-controlled asthma (ACT score ≥20).

    Time frame: At baseline, week 12, 24 and 52

  3. Change in daily doses of prescribed inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose

    To assess prescribed daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.

    Time frame: From baseline to week 12, 24 and 52

  4. Change in daily doses of patient-reported inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose

    To assess patient-reported daily ICS dose of benralizumab treated patients over time. Doses of medication will be converted to equivalents to be able to make comparisons.

    Time frame: From baseline to week 12, 24 and 52

  5. Reduction (in percentage) in prescribed daily ICS dose intake from baseline to week 52 after first benralizumab dose

    To assess prescribed daily ICS dose of benralizumab treated patients with ICS dose reduction.

    Time frame: From baseline to week 52

  6. Reduction (in percentage) in patient-reported daily ICS dose intake from baseline to week 52 after first benralizumab dose

    To assess patient-reported daily ICS dose of benralizumab treated patients with ICS dose reduction.

    Time frame: From baseline to week 52

Secondary outcomes

  1. Proportion of patients meeting any individual criteria for remission at baseline, week 24 and 52 after first benralizumab dose

    To describe the proportion of patients who meet any individual criteria for remission. Criteria for remission are defined as no exacerbation, no prescribed use of oral corticosteroids (OCS) for asthma, ACT score ≥20, and stable lung function).

    Time frame: At baseline, week 24 and 52

  2. Proportion of patients fulfilling all the criteria for remission at baseline, week 24 and 52 after first benralizumab dose

    To describe the proportion of patients who meet all criteria for remission after initiation of benralizumab treatment.

    Time frame: At baseline, week 24 and 52

  3. Total Asthma Impairment and Risk Questionnaire® (AIRQ®) score reduction from baseline to every 4 weeks after first benralizumab dose

    To assess diaries reported asthma control in patients initiating treatment with benralizumab using the AIRQ® score. The AIRQ® includes 10 questions (7 assessing symptom impairment and 3 assessing risk) concerning patient medication use, asthma symptoms, medical visits, and tests. The AIRQ® can predict the risk for exacerbations and assess the quality of life of asthma patients. AIRQ® score: well-controlled (0-1 points), not well-controlled (2-4 points) and very poorly controlled (≥5 points) asthma

    Time frame: From baseline to week 52

  4. Total ACT score reduction from baseline to every 4 weeks after first benralizumab dose

    To assess diaries reported asthma control in patients initiating treatment with benralizumab using the ACT score.

    Time frame: From baseline to week 52

  5. Change in total Mini Asthma Quality of Life Questionnaire (miniAQLQ) score from baseline to week 12, 24, and 52 after first benralizumab dose

    To describe patient-reported health-related quality of life (HRQL) in patients initiating treatment with benralizumab using the miniAQLQ. The miniAQLQ is composed of 15 questions covering 4 different domains, namely symptoms, activities, emotions, and environment experienced during the previous 2 weeks. The score in each item can vary from 1 to 7, with a higher score indicating better quality of life (QoL). The mean score is calculated as the total score divided by the number of items, and the domain scores are calculated as the total score divided by the number of items for respective domain. A change in score of ≥0.5 can be considered clinically important

    Time frame: From baseline to week 12, 24 and 52

  6. Change in daily doses of prescribed relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose

    To describe the proportion of patients regarding prescribed standard-of-care (SOC) asthma medication dose change in patients initiating treatment with benralizumab.

    Time frame: From baseline to week 12, 24 and 52

  7. Proportion of patients with increased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose

    To describe the proportion of patients regarding prescribed increased SOC asthma medication dose in patients initiating treatment with benralizumab.

    Time frame: From baseline to week 12, 24 and 52

  8. Proportion of patients with decreased daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose

    To describe the proportion of patients regarding prescribed decreased SOC asthma medication dose in patients initiating treatment with benralizumab.

    Time frame: From baseline to week 12, 24 and 52

  9. Proportion of patients with equal daily dose of relevant background medication from baseline to week 12, 24 and 52 after first benralizumab dose

    To describe the proportion of patients regarding prescribed equal SOC asthma medication dose in patients initiating treatment with benralizumab.

    Time frame: From baseline to week 12, 24 and 52

  10. Annualized exacerbation rate assessed at baseline, week 12, 24 and 52 after first benralizumab dose

    To assess the annualized asthma exacerbation rate in patients initiating treatment with benralizumab.

    Time frame: From baseline to week 12, 24 and 52

  11. Proportion of patients without exacerbations at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the proportion of patients without asthma exacerbations in patients initiating treatment with benralizumab.

    Time frame: From baseline to week 12, 24 and 52

  12. Level of lung function parameters - forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the FEV1 and FVC levels in patients initiating treatment with benralizumab. From FEV1 and FVC the Tiffenau-Index will be calculated as follows: FEV1/FVC

    Time frame: At baseline, week 12, 24 and 52

  13. Level of lung function parameters - residual volume (RV) at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the level of RV in patients initiating treatment with benralizumab.

    Time frame: At baseline, week 12, 24 and 52

  14. Level of lung function parameters - total lung capacity (TLC) at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the level of TLC in patients initiating treatment with benralizumab.

    Time frame: At baseline, week 12, 24 and 52

  15. Level of lung function parameters - total specific airway resistance (sRtot) at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the level of sRtot in patients initiating treatment with benralizumab.

    Time frame: At baseline, week 12, 24 and 52

  16. Level of diffusing capacity of the lungs for carbon monoxide (DLCO) at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the level of DLCO in patients initiating treatment with benralizumab.

    Time frame: At baseline, week 12, 24 and 52

  17. Level of biomarkers - eosinophils at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the level of eosinophils in patients initiating treatment with benralizumab. Measured in cells per microliter.

    Time frame: At baseline, week 12, 24 and 52

  18. Level of biomarkers - total immunglobulin E (IgE) at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the level of total IgE in patients initiating treatment with benralizumab. Total IgE, measured in international units per milliliter (IU/ml).

    Time frame: At baseline, week 12, 24 and 52

  19. Level of biomarkers - fractional exhaled nitric oxide (FeNO) at baseline, week 12, 24 and 52 after first benralizumab dose

    To describe the level of FeNO in patients initiating treatment with benralizumab. Measured in parts per billion (ppb).

    Time frame: At baseline, week 12, 24 and 52

07

Study locations

40 of 41 sites recruiting
  • Research Site
    Ahrensburg, Germany
    Recruiting
  • Research Site
    Ansbach, Germany
    Recruiting
  • Research Site
    Aschaffenburg, Germany
    Recruiting
  • Research Site
    Auerbach, Germany
    Recruiting
  • Research Site
    Augsburg, Germany
    Recruiting
  • Research Site
    Bad Homburg, Germany
    Recruiting
  • Research Site
    Berlin, Germany
    Recruiting
  • Research Site
    Cottbus, Germany
    Recruiting
  • Research Site
    Darmstadt, Germany
    Recruiting
  • Research Site
    Dresden, Germany
    Recruiting
  • Research Site
    Düsseldorf, Germany
    Recruiting
  • Research Site
    Ehringshausen, Germany
    Recruiting
  • Research Site
    Erkelenz, Germany
    Recruiting
  • Research Site
    Essen, Germany
    Recruiting
  • Research Site
    Flensburg, Germany
    Recruiting
  • Research Site
    Frankfurt am Main, Germany
    Recruiting
  • Research Site
    Garmisch-Partenkirchen, Germany
    Recruiting
  • Research Site
    Halle, Germany
    Recruiting
  • Research Site
    Hamburg, Germany
    Recruiting
  • Research Site
    Hanover, Germany
    Recruiting
  • Research Site
    Heidelberg, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Heidelberg, Germany
    Recruiting
  • Research Site
    Hohenstein-Ernsttahl, Germany
    Recruiting
  • Research Site
    Itzehoe, Germany
    Recruiting
  • Research Site
    Jena, Germany
    Recruiting
  • Research Site
    Leipzig, Germany
    Recruiting
  • Research Site
    Loerrach, Germany
    Recruiting
  • Research Site
    Lübeck, Germany
    Recruiting
  • Research Site
    Lüneburg, Germany
    Recruiting
  • Research Site
    Markkleeberg, Germany
    Recruiting
  • Research Site
    Mönchengladbach, Germany
    Recruiting
  • Research Site
    Neuruppin, Germany
    Recruiting
  • Research Site
    Nuremberg, Germany
    Recruiting
  • Research Site
    Papenburg, Germany
    Recruiting
  • Research Site
    Rostock, Germany
    Recruiting
  • Research Site
    Saalfeld, Germany
    Recruiting
  • Research Site
    Spardorf, Germany
    Recruiting
  • Research Site
    Weißenburg, Germany
    Recruiting
  • Research Site
    Wilhelmshaven, Germany
    Recruiting
  • Research Site
    Würzburg, Germany
    Recruiting
  • Research Site
    Zossen, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 41 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 20, 2024
StartActual
Jul 25, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06422078
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Jul 25, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 28, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion